The medical technology company Kontigo Care reports slightly higher revenue and a reduced operating loss in the second quarter compared with the same period a year earlier.Revenue rose 1.8 percent to SEK 7.2 million (7.0).EBITDA excluding capitalized development expenses amounted to SEK 0.8 million (-2.1), with an EBITDA margin of 10.9 percent.Operating profit was SEK -1.1 million (-1.4).The company states that comparability with the previous year is affected by expenses for ongoing product development being expensed rather than capitalized since April 1. In the comparison quarter, development expenses of SEK 2.2 million were capitalized, while no such expenses were capitalized during the second quarter of this year.Net profit amounted to SEK -1.0 million (-1.4). Earnings per share were SEK -0.03 (-0.04).Cash and cash equivalents amounted to SEK 13.2 million (16.2) at the end of the period.MRR, monthly recurring revenue, amounted to SEK 2.35 million (2.37) at the end of June, corresponding to a decrease of 0.8 percent compared with a year earlier."The second quarter shows that the existing business continues to develop well while we are taking concrete steps toward an international presence. Revenue development during the quarter was stable, while the cost discipline we established in Q1 remains in place," writes CEO Alex Stendahl. Kontigo Care provides no guidance.Key figures, SEK millionQ2 2026Q2 2025Year-over-year changeRevenue7.27.01.8%EBITDA excl. capitalized development expenses0.8-2.1-EBITDA margin10.9%-30.3%-EBIT-1.1-1.4-Net profit-1.0-1.4-Earnings per share, SEK-0.03-0.04-Cash and cash equivalents13.216.2-18.5%